Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) but lowers the price target from $8 to $6.
August 13, 2024 | 10:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Serge Belanger maintains a Buy rating on Esperion Therapeutics but lowers the price target from $8 to $6.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations for short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100